ATE309267T1 - Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür - Google Patents

Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür

Info

Publication number
ATE309267T1
ATE309267T1 AT95918912T AT95918912T ATE309267T1 AT E309267 T1 ATE309267 T1 AT E309267T1 AT 95918912 T AT95918912 T AT 95918912T AT 95918912 T AT95918912 T AT 95918912T AT E309267 T1 ATE309267 T1 AT E309267T1
Authority
AT
Austria
Prior art keywords
cells
proliferation
differentiation
proliferating
present
Prior art date
Application number
AT95918912T
Other languages
English (en)
Inventor
Marilyn Kehry
Brian E Castle
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE309267T1 publication Critical patent/ATE309267T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT95918912T 1994-04-28 1995-04-28 Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür ATE309267T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23458094A 1994-04-28 1994-04-28
PCT/US1995/005448 WO1995029935A1 (en) 1994-04-28 1995-04-28 Method for proliferating and differentiating b cells, and uses thereof

Publications (1)

Publication Number Publication Date
ATE309267T1 true ATE309267T1 (de) 2005-11-15

Family

ID=22881963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918912T ATE309267T1 (de) 1994-04-28 1995-04-28 Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür

Country Status (10)

Country Link
US (2) US5817516A (de)
EP (1) EP0763057B1 (de)
JP (1) JP3881691B2 (de)
AT (1) ATE309267T1 (de)
CA (1) CA2188165C (de)
DE (1) DE69534595T2 (de)
DK (1) DK0763057T3 (de)
ES (1) ES2251719T3 (de)
MX (1) MX9605088A (de)
WO (1) WO1995029935A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ATE309267T1 (de) * 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
AU5590198A (en) * 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Method of promoting b-cell proliferation and activation and of modulating the immune system
US6465251B1 (en) 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP2039368A3 (de) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Verfahren zur Vorbeugung der Reaktivierung von latenten Viren und Überwachung der Virenreplikation
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
ES2384960T3 (es) * 2001-12-18 2012-07-16 Cancer Research Technology Limited Procedimiento para la generación de líneas celulares proliferativas y que se diferencian
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
JP2008528010A (ja) * 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
EP1928999B1 (de) 2005-08-23 2011-04-13 IQ Corporation Verfahren zur herstellung stabiler b-lymphozyten
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
US8703486B2 (en) 2008-09-23 2014-04-22 UNIVERSITé LAVAL Method for polyclonal immunoglobulin G production by human B cells
JP5550132B2 (ja) 2009-10-30 2014-07-16 学校法人東京理科大学 抗原特異的ｂ細胞集団の製造方法
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
EP3165602B1 (de) 2014-07-02 2020-12-09 Tokyo University of Science Foundation Verfahren zur herstellung einer b-zellpopulation
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
GB201707238D0 (en) 2017-05-05 2017-06-21 Univ Oxford Innovation Ltd Composition
KR102539610B1 (ko) * 2020-01-22 2023-06-02 한국생명공학연구원 메모리 b 세포 특이적 분화 유도 방법 및 이의 활용
KR20240024781A (ko) * 2021-04-19 2024-02-26 워킹 피쉬 테라퓨틱스 인코포레이티드 세포 요법에 사용하기 위한 b 세포 확장의 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
EP0434879A1 (de) 1989-12-14 1991-07-03 Schering-Plough Verfahren zur Herstellung von faktorabhÀ¤ngigen menschlichen B-Zellinien
JPH06500023A (ja) 1991-05-16 1994-01-06 イーデーテー　アーゲー　フュア　イン　ビーフォ　ディアグノスティーク　ウント　テラピー 抗原特異性ｂおよびｔリンパ球ならびにそれから得られるモノクローナル抗体を提供する方法
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
DE4322330A1 (de) 1992-08-31 1994-03-03 Behringwerke Ag Verwendung des IL-4-Rezeptors zur Therapie, Prophylaxe und Diagnose von allergischen, viralen, parasitären und bakteriellen Erkrankungen sowie von Pilzinfektionen
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ATE309267T1 (de) * 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür

Also Published As

Publication number Publication date
EP0763057A1 (de) 1997-03-19
US5817516A (en) 1998-10-06
JP3881691B2 (ja) 2007-02-14
US6297052B1 (en) 2001-10-02
MX9605088A (es) 1997-08-30
DE69534595D1 (de) 2005-12-15
ES2251719T3 (es) 2006-05-01
CA2188165C (en) 2007-08-28
CA2188165A1 (en) 1995-11-09
JPH09512441A (ja) 1997-12-16
DE69534595T2 (de) 2006-05-24
EP0763057A4 (de) 1998-11-11
DK0763057T3 (da) 2006-03-27
WO1995029935A1 (en) 1995-11-09
EP0763057B1 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
DE69534595D1 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
ES2120946T3 (es) Sistemas y medios de cultivo celular.
EP1025204A4 (de) Methoden und materialien zur kultivierung von von primaten abgeleiteten primordialen stammzellen
YU45871B (sh) Polipeptid sa humanim imunointerferonskim (ifn-gama) svojstvima
ATE406435T1 (de) Methoden zur züchtung von tierzellen
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
EP1023451A4 (de) Methoden zur replikation von viren in von monozyten abgeleiteten makrophagenkulturen
EP0682697A4 (de) Methode und gerät zur verankerung und suspension von zellkulturen.
ATE153214T1 (de) Medien zur zellzucht und verfahren dazu
DE69638077D1 (de) Bakterielle Produktion von Interferon-beta Polypeptiden
ES8700320A1 (es) Metodo de obtencion del exprimido de una materia seleccionada que contiene renina.
ATE161041T1 (de) Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
DE3476221D1 (en) Method for obtaining human hepatocytes cultures, cultures obtained thereby and biological and biochemical applications thereof
EP0871645A4 (de) Vorrichtung und verfahren zur geteilten behandlung von abwasser
ES2176224T3 (es) Proceso para la produccion de proteina.
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
ATE132896T1 (de) Methoden zur verwendung von an humanen klasse-ii- histokompatibilitätsantigenen mangelnden zellinien
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
DK0706567T3 (da) Peptidfamilie betegnet xenoxiner
EP1091765A4 (de) Verfahren zur reduzierung von zufällig auftretenden toxinen und dadurch produzierte zellkulturreagenzien
DE3871322D1 (de) Verfahren zur kultur von pflanzengewebe.
DE69014723D1 (de) Zellzüchtungsverfahren.
ATE49777T1 (de) Verfahren zur zuechtung von hepatozyten und cozuechtung von hepatozyten und von behandelten epithelien leberzellen.
FR2815968B1 (fr) Fractions membranaires de cellules enrichies en 1,2-sn- diacylglycerol, procede de preparation et utilisations
FI974043A0 (fi) Foerfarande foer att odla mikrobiologiska prov

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0763057

Country of ref document: EP